AOD9604 is often introduced through its relationship to growth hormone. That relationship needs a precise molecular description: a fragment with an added residue is not the complete hormone. Its research history also contains different questions, from metabolic responses in mice to selected safety observations in human trials. Reading those questions separately gives a more useful account than a general fat-loss label.
Translate the fragment name into a molecular reference
The 2013 clinical-programme report describes AOD9604 as Tyr-hGH 177–191 and prints the sequence YLRIVQCRSVEGSCGF. The added N-terminal tyrosine makes this a 16-residue peptide rather than the unmodified 15-residue hormone segment.Stier, Vos and Kenley — Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (opens in a new tab)
Novum’s supplied 5 mg report also prints this sequence and describes disulfide mapping between cysteines at positions 7 and 14. These are positions within the displayed peptide, not residue numbers in the complete hormone.Supplied AOD9604 5 mg report (opens in a new tab)
| Notation | Meaning in this comparison |
|---|---|
| 177–191 | Positions of the parent hormone segment |
| N-terminal Tyr | Additional residue preceding that segment |
| Cys7–Cys14 | Disulfide positions in the supplied 16-residue sequence |
Keeping both numbering systems visible prevents an apparent discrepancy from becoming an incorrect sequence correction. A literature note should also retain whether the material is described in its disulfide-linked form.
The supplied report is a document about its identified sample. Reading its identity statement does not independently authenticate the report or establish equivalence to a historical trial preparation.
Read the knockout experiment as a mechanistic comparison
Heffernan and colleagues examined AOD9604 in obese mice and mice lacking the beta-3 adrenergic receptor. Their 2001 report connected metabolic responses to this experimental context and described loss of the weight and lipolysis responses in the knockout animals.Heffernan and colleagues — AOD9604 in obese and beta(3)-AR knockout mice (opens in a new tab)
A knockout comparison asks what happens when a biological component is absent. It can support that component’s involvement under the tested conditions; it does not by itself demonstrate direct binding of the peptide to that receptor.
This distinction changes the wording of a mechanism summary. A beta-3-receptor-dependent observation is narrower than calling AOD9604 a proven direct beta-3 agonist.
The animal phenotype and the molecular explanation also remain separate. A change in mouse body weight does not establish the same response in people, nor identify every tissue contributing to the observed change.
Keep the clinical report within its stated purpose
Stier, Vos and Kenley’s 2013 paper summarises safety and tolerability data from six placebo-controlled human trials. It reports selected metabolic, laboratory and adverse-event observations; its declared purpose is a safety analysis, not a complete efficacy account.Stier, Vos and Kenley — Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (opens in a new tab)
The full text records a severe diarrhoea event assessed as possibly related in one study. That detail should not disappear behind a blanket statement that no potentially related serious events occurred. The paper also discloses company funding and author financial interests.Stier, Vos and Kenley — Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (opens in a new tab)
These observations justify reading the human programme, but they do not supply a universal safety guarantee. They also cannot be used as a substitute for the body-weight results and analysis required to assess a weight-loss claim.
Build an AOD9604 evidence note that can be updated
Start the note with the exact sequence and fragment alias, then make separate entries for the mouse comparison and human safety report. Record the measured endpoint beside each entry so their conclusions cannot be silently combined.
For a new paper, first check whether its preparation matches the identity in the note. Then establish whether it adds binding evidence, a model-specific outcome, clinical efficacy or further safety follow-up.
This creates a useful place for future evidence without turning a historical development programme into a present-day product promise. A vial label, a structural relationship and a clinical outcome are three different pieces of information.
Sources and further detail
- Supplied AOD9604 5 mg report (opens in a new tab)
Complete supplied PDF read for the sequence and Cys7–Cys14 mapping statement. Document transcription only; no authentication or trial-material equivalence claimed.
- Heffernan and colleagues — AOD9604 in obese and beta(3)-AR knockout mice (opens in a new tab)
Original 2001 abstract and author metadata read. Receptor-dependence observation distinguished from direct agonist evidence; no administration details reproduced.
- Stier, Vos and Kenley — Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (opens in a new tab)
Full 2013 identity, study-purpose, adverse-event and disclosure sections read. Possibly related severe diarrhoea retained; broad safety, efficacy and regulatory claims not adopted.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.